Hayley Virgil


Adjuvant Nivolumab/Ipilimumab Falls Short of RFS End Point in Resected, Late-Stage Melanoma

April 10th 2021

The addition of ipilimumab to nivolumab as an adjuvant treatment failed to improve relapse-free survival in the intent-to-treat and PD-L1 of less than 1% populations compared with nivolumab alone in patients with resected stage IIIB to D/IV melanoma.

Abu-Zeinah Shares Next Steps for Research With Interferon-Alpha in Polycythemia Vera

April 9th 2021

Now that interferon-alpha has been shown to prolong survival in patients with polycythemia vera, it is important that investigative efforts focus on developing a better understanding on the biology of the disease and the mechanisms by which the agent actually improves outcomes.

Matsen Spotlights Best Practices for Breast Cancer Surgery Amidst the COVID-19 Crisis

April 7th 2021

The coronavirus disease 2019 pandemic had a tremendous impact on the surgical care of patients with breast cancer; practice patterns needed to be rapidly adjusted to continue to safely provide care during a time when resources were very limited.

Searching for Molecular Targets in Myeloid Malignancies and Beyond

April 6th 2021

Ulrich Steidl, MD, PhD, discusses translational research efforts that have been made with targeting leukemia stem cells and ongoing clinical trials that are examining novel therapeutic targets in myeloid malignancies and beyond.

Utility of HRD Testing in Ovarian Cancer Expands, But Standardization Remains Elusive

April 6th 2021

Two tests for homologous recombination deficiency have been FDA approved for patients with ovarian cancer, including myChoice CDx and FoundationOne CDx, and they produce important information that can be used to guide treatment decisions.

D-VCd Rises as the New Standard of Care in Newly Diagnosed AL Amyloidosis

April 6th 2021

Jonathan L. Kaufman, MD, discusses the significance of subcutaneous D-VCd in the treatment of patients with AL amyloidosis, remaining questions with the approach, and emerging strategies for those with high-risk cardiac features.

Immunotherapy Agents Demonstrate Groundbreaking Data in GI Cancers

April 5th 2021

Lakshmi Rajdev, MD, discusses some of the key developments made with immunotherapy in gastrointestinal cancers and the groundbreaking data that have recently read out to support their use.

Abu-Zeinah Outlines Why Interferon-Alpha Should Be Offered to Both Low- and High-Risk Polycythemia Vera

April 5th 2021

Ghaith Abu-Zeinah, MD, shares what inspired the study examining IFN vs standard strategies, key findings from the research, and the clinical implications of these data on the PV treatment paradigm.

Shastri Stresses the Need for Risk Stratification to Personalize Decisions in MDS

March 29th 2021

Aditi Shastri, MBBS, discusses risk stratification tools, her treatment algorithm for patients with low-risk MDS, and the role of luspatercept in this population.

Single Priming Dose of Tremelimumab Plus Durvalumab Shows Encouraging Clinical Activity, Safety in Advanced HCC

March 28th 2021

A regimen comprised of a single 300-mg priming dose of tremelimumab and 1500 mg of durvalumab every 4 weeks yielded favorable efficacy and an acceptable safety profile in patients with advanced HCC.